To better understand the tumor-control advantage of CAR-T cells inhibiting ADAM17, we assessed the proportions and phenotypes of these tumor-infiltrating CAR-T cells 7 days after adoptive transfer (supplementary Fig. 8g). This evidence concerns the gene ADAM17 and neoplasm.